Streetbeat News

Products Services

BDRX

Biodexa Pharmaceuticals (NASDAQ: BDRX) will present 12-month Phase 2 clinical trial results of eRapa in Familial Adenomatous Polyposis at the InSIGHT 2024 meeting in Barcelona. The presentation will be given by Dr. Carol Burke, who previously presented six-month data at the Digestive Disease Weekly meeting.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:31 pm

SRZN

Surrozen presented preliminary results of its Phase 1a study of SZN-043 in liver cirrhosis patients at EASL 2024. The treatment was safe and well tolerated, showing evidence of target engagement and Wnt-pathway mediated effects. Enrollment is ongoing for the Phase 1b study in severe alcohol-associated hepatitis.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:30 pm

SKYE

Skye Bioscience shares are trading lower after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve the target product profile and has discontinued the program.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:25 pm

SKYE

Skye Bioscience announced that its Phase 2a trial of SBI-100 OE in glaucoma patients did not meet the primary endpoint. As a result, the company will discontinue related R&D and shift focus to its metabolic program, with a Phase 2 obesity trial for Nimacimab set to begin dosing in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:21 pm

TU

TELUS is set to invest $33 million in Montreal in 2024 to enhance its 5G networks and connect businesses with optic fibre. As part of a sponsorship agreement with CF Montréal, TELUS will also invest $1.2 million to improve wireless connectivity at Stade Saputo.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:16 pm

GM

MRK

NKE

XLE

On CNBC's 'Halftime Report Final Trades,' analysts recommended The Energy Select Sector SPDR Fund (XLE), General Motors (GM), Merck (MRK), and Nike (NKE). GM reported strong Q1 2024 results, Merck announced positive study results with Moderna, and Nike is reducing its workforce to save costs.

Portfolio Pulse from Avi Kapoor

June 10, 2024 | 12:14 pm

HOTH

NVDA

Hoth Therapeutics shares are trading higher following the announcement of a joint development agreement with Wise Systems International to utilize Nvidia's BioNeMo AI platform.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:14 pm

HOTH

NVDA

Hoth Therapeutics has entered into a joint development agreement with Wise Systems International SRL to utilize Nvidia's BioNeMo AI platform for drug discovery. This collaboration aims to accelerate the training of models on proprietary data using generative AI.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:13 pm

RTX

RTX has been awarded a $677 million contract by the U.S. Navy to provide N/SPY-6(V) radars. This contract is expected to enhance RTX's revenue and strengthen its position in the defense sector.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:12 pm

MTEK

Maris-Tech has received a $957K repeat order for its customized AI video solution aimed at enhancing situational awareness in armored and autonomous vehicles. The delivery is expected by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 12:11 pm